Last modified
12/18/2018 - 02:59

FDA approves Ilumya (tildrakizumab)

What is the drug for?

ILUMYA is a drug for treatment of moderate to severe plaque psoriasis, in adults, who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

Name: Tildrakizumab
CAS No.: 1326244-10-3
Chemical Names: GTPL8093; MK-3222

How is this drug used?

ILUMYA is an injection given under the skin. The first two injections are given 4 weeks apart, followed by an injection once every 12 weeks.

What are the benefits of this drug?

ILUMYA was better than placebo in improving symptoms of plaque psoriasis and maintaining the improvement through at least a year of treatment.

Were there any differences in how well the drug worked in clinical trials among sex, race and age?

  • Sex: ILUMYA worked similarly in men and women.
  • Race: The majority of patients were White. The number of patients in other races was limited; therefore, differences in response among races could not be determined.
  • Age: The number of patients above 65 years of age was limited; therefore, differences in response between patients above and below 65 years of age could not be determined.




Send inquiry online For more product information and prices

(Pharmaceutical Ingredients Manufacturer & Supplier & Exporter.)

After sending the online inquiry, we will reply you as soon as possible, if not get any response on time please contact us by Tel or Email. —— Green Stone Swiss

Tel: +86 592 5365887
WhatsApp: +86 189 6515 7632
Send inquiry online: